Bioptik Technology (4161) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bioptik Technology (4161) has a cash flow conversion efficiency ratio of 0.055x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$53.21 Million ≈ $1.68 Million USD) by net assets (NT$974.69 Million ≈ $30.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4161 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Bioptik Technology - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Bioptik Technology's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bioptik Technology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioptik Technology ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trisula Textile Industries Tbk PT
JK:BELL
|
0.074x |
|
Insung Information Co. Ltd
KQ:033230
|
-0.098x |
|
Marketwise Inc
NASDAQ:MKTW
|
0.009x |
|
Information and Communication Networks Public Company Limited
BK:ICN
|
0.114x |
|
Public Packages Holdings Bhd
KLSE:8273
|
0.096x |
|
Mad Paws Holdings Ltd
AU:MPA
|
0.133x |
|
HPQ SILICON INC.
F:O08
|
-0.051x |
|
IFirma SA
WAR:IFI
|
0.126x |
Annual Cash Flow Conversion Efficiency for Bioptik Technology (2017–2025)
The table below shows the annual cash flow conversion efficiency of Bioptik Technology from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Bioptik Technology worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$974.69 Million ≈ $30.71 Million |
NT$59.99 Million ≈ $1.89 Million |
0.062x | -64.92% |
| 2024-12-31 | NT$905.27 Million ≈ $28.52 Million |
NT$158.82 Million ≈ $5.00 Million |
0.175x | -29.79% |
| 2023-12-31 | NT$824.15 Million ≈ $25.97 Million |
NT$205.95 Million ≈ $6.49 Million |
0.250x | +225.81% |
| 2022-12-31 | NT$717.83 Million ≈ $22.62 Million |
NT$55.06 Million ≈ $1.73 Million |
0.077x | +229.45% |
| 2021-12-31 | NT$694.54 Million ≈ $21.88 Million |
NT$-41.15 Million ≈ $-1.30 Million |
-0.059x | -763.13% |
| 2020-12-31 | NT$735.66 Million ≈ $23.18 Million |
NT$6.57 Million ≈ $207.09K |
0.009x | -83.27% |
| 2019-12-31 | NT$768.38 Million ≈ $24.21 Million |
NT$41.03 Million ≈ $1.29 Million |
0.053x | +3.64% |
| 2018-12-31 | NT$811.73 Million ≈ $25.57 Million |
NT$41.83 Million ≈ $1.32 Million |
0.052x | +314.97% |
| 2017-12-31 | NT$887.42 Million ≈ $27.96 Million |
NT$11.02 Million ≈ $347.16K |
0.012x | -- |
About Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also p… Read more